The US Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA; Gleolan ® ; photonamic GmbH and Co. KG) for use as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs) in 2017. This was the first ever optical imaging agent approved as an adjunct for the visualization of malignant tissue during surgery for brain tumors. The approval occurred a decade after European approval and a multicenter, phase III randomized trial which confirmed that surgeons using 5-ALA fluorescence-guided surgery as a surgical adjunct could achieve more complete resections of tumors in HGG patients and better patient outcomes than with conventional microsurgery. Much of the delay in the US FDA approval of 5-ALA stemmed from its conceptualization as a therapeutic and not as an intraoperative imaging tool. We chronicle the challenges encountered during the US FDA approval process to highlight a new standard for approval of intraoperative optical imaging agents in brain tumors.
Introduction
In June of 2017, the US Food and Drug Administration (FDA) approved oral Gleolan ® 5-aminolevulinic acid (5-ALA) hydrochloride; photonamic GmbH and Co. KG for use as an optical imaging agent in patients with gliomas [suspected World Health Organization Grades III or IV high-grade gliomas (HGGs) on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery [1] . This heralded the US approval of the firstever optical imaging agent for use with brain tumors during fluorescence-guided surgery (FGS).
The FDA approval of 5-ALA for HGGs occurred 10 years after the approval by the European Medicine's Agency (EMA) in 2007 and close to two decades after Dr. Walter Stummer's initial description of 5-ALA FGS in human patients ( Fig. 1) [2, 3] . Here we describe the FDA process for 5-ALA approval in the US and some of the challenges faced during this journey that took years for fruition. We hope this may help other future intraoperative optical imaging agents move forward with FDA approval for use in tumor visualization in patients.
FDA approved drugs/devices in brain tumors
Currently there are five drugs and one device approved by the FDA for brain tumors in the US including 5-ALA. The first drugs to be FDA approved for HGGs were oral lomustine (CeeNU ® ; Bristol-Myers Squibb, Princeton, NJ), which received approval in 1976 [4] , and intravenous carmustine (BiCNU ® ; Bristol-Myers Squibb) which received approval in 1977 [5] . These nitrosoureas were approved as single agents or in combination with other chemotherapeutic agents in patients with HGG tumors who have already undergone surgery and/ or radiation therapy. In both drugs, FDA approval was based on the tumor response rate of patients treated. Intraoperative carmustine chemotherapy wafer implants (Gliadel ® wafers; Arbor Pharmaceuticals, Inc.) were approved by the FDA in 1996 for recurrent HGGs [6] . In 2003, these chemotherapy implants were approved for new HGGs [7, 8] . The approval 1 3 of carmustine wafers was based on a significant increase in overall survival (OS) of patients in comparison to placebo control groups. Temozolomide (Temodar ® ; Merck and Co., Inc.) chemotherapy was granted approval for recurrent anaplastic astrocytomas in 1999 and newly diagnosed glioblastoma (GBM) in 2005 [9, 10] . The approval of temozolomide for newly diagnosed GBM was based on the largest OS increase to date in HGG patients undergoing adjuvant and concurrent treatment after fractionated external beam radiotherapy [11] .
Bevacizumab (Avastin ® ; Genentech Corp.) chemotherapy was approved for recurrent GBM in 2009 [12] . The clinical trial that was completed for FDA approval was a randomized, non-comparative (non-controlled), multicenter trial to evaluate the efficacy and safety of bevacizumab alone or in combination with irinotecan. The approval of bevacizumab was based on the progression-free survival rate at 6 months (PFS-6) and the durable objective response rate of patients (independent radiologic review and stable or decreasing corticosteroid use) [12] [13] [14] .
The Optune device (Novocure, Inc.), which utilizes alternating electric fields (tumor treatment fields) rather than chemotherapy, was approved for recurrent GBM in 2011 and newly diagnosed GBM in 2015 [15] [16] [17] [18] . Both of these approvals were based on randomized, controlled studies. In the recurrent GBM setting, there was no improvement in OS, however, efficacy and activity with the device was comparable to chemotherapy regimens commonly used for recurrent GBM. In newly diagnosed GBM patients, there was a significant OS and PFS patient benefit.
5-ALA history
In 2006, the landmark 5-ALA multicenter, randomized phase III study, led by Dr. Walter Stummer, confirmed that surgeons using 5-ALA FGS as a surgical adjunct could achieve more complete resections of tumors in HGG patients and better patient outcomes than with conventional microsurgery [19] . Complete resection of the enhancing portion of newly diagnosed HGGs occurred in 65% of patients assigned to the 5-ALA group versus 36% in those assigned to the conventional surgery white light group (difference between groups 29% [95% CI , p < 0.0001). In addition to greater complete resections, overall PFS-6 was also significantly greater after 5-ALA FGS (41.0% [32.8-49 .2] vs. 21.1% [14.0-28.2] ; p = 0.0003). Safety was also established by the phase III study with use of 5-ALA FGS. No deaths were attributed to the actual use of 5-ALA and there were no significant differences in the NIH stroke scale scores for patients in both arms of the study at 6 weeks post-surgery [20] . There was no detectable difference in OS of patients in the study, however, as the phase III was not powered to be an OS study. Furthermore, during the course of the study, the Stupp regimen (concurrent and adjuvant temozolomide after fractionated external beam radiotherapy), which is widely considered a standard of care for HGG patients, was not routinely administered at that time. The results of this study led to approval of 5-ALA (Gliolan ® , photonamic 
Patient clinical benefit
The FDA was initially approached by a group of medical experts (four neurosurgeons and a radiation-oncologist) and industry [NX Development Corp. (NXDC) and photonamic GmbH and Co.] in 2011 to discuss the approval process of 5-ALA in the US. The European clinical experience, including the randomized, phase III study results, was provided for consideration by the FDA. Two years prior in 2009, the FDA approval of bevacizumab for recurrent GBM was based on a non-comparative study and the "objective response" of patients treated with bevacizumab [12] . The Oncologic Drugs Advisory Committee (ODAC) held a Public Workshop on Clinical Trial End Points in Primary Brain Tumors in 2006 to define an "objective response" to treatment [21] . ODAC stated that an "objective response could be an adequate surrogate for clinical benefit under the proper parameters". Workshop discussants agreed that a response rate of sufficient magnitude (e.g. > 30%) was likely to be associated with clinical benefit. The convincing phase III data showing safety, a close to doubling of the extent of resection (EOR) of HGGs, and a significant PFS-6 with 5-ALA FGS was discussed.
The FDA Advisory Group, which included members of the Division of Medical Imaging Products and ODAC, felt that further patient clinical benefit in addition to PFS-6 was needed for consideration of 5-ALA approval since the phase III study did not provide a treatment specific OS benefit to patients (even though it was not powered to do so). The FDA requested evidence that 5-ALA FGS provided additional clinical benefit to patients who otherwise would undergo conventional surgical resection. What did this mean? The prospect of a randomized controlled study utilizing 5-ALA FGS in HGG patients for assessing OS as a primary endpoint was daunting. ODAC, at the time, was considering 5-ALA as a therapeutic agent, rather than an adjunct visualization agent and, given this assumption, it was only logical that the FDA should require an outcomes trial. However, the obvious misconception in this assumption was that 5-ALA was envisioned as an imaging tool used by surgeons to improve resection. Surgical resection was the driver of outcome, with resection being driven by much more than simply the knowledge of tumor location, leading to an inflation of patient numbers. HGG disease-related variables including genomics (IDH mutational and MGMT methylation status), frequency of treatment interventions, the lack of ability to control salvage therapy, and the use of surgery at the time of recurrence impacted upon power calculations and the number of patients that would be required to properly design an OS trial [22] . As a result, it became apparent that a properly designed trial would be beyond the scope of the next decade in this orphan disease.
The large patient numbers, lengthy time needed for patient enrollment, and high costs required to conduct such a study were prohibitive even with the prospect of teaming up with well-known cooperative groups that have experience completing such large randomized studies in HGG patients [e.g. Radiation Therapy Oncology Group (RTOG)]. Furthermore, randomized OS clinical studies with HGG patients are challenged by clinical equipoise and the high likelihood of patients leaving the study at recurrence to enroll into other trials that are actually therapeutic.
Utilization of quality of life (QOL) as a primary endpoint for clinical benefit in a randomized 5-ALA FGS study was one strategy pursued with guidance by the RTOG [23] [24] [25] [26] [27] . At the time, completion of the large, randomized studies for assessing the benefit of dose-dense temozolomide (RTOG 0525) [28] and bevacizumab (RTOG 0825) [29] in newly diagnosed GBM patients served as a data source to assess whether QOL could associated with greater tumor EOR. In both studies, QOL metrics were measured in each arm in addition to tumor EOR. Unfortunately, QOL was not definitively associated with EOR in those studies and EOR analyses in both studies were not performed with rigorous volumetric methods.
Surgical trial bias
Attempts were made to initiate a randomized, placebo-controlled multicenter trial of 5-ALA and FGS in combination with conventional chemoradiation and adjuvant temozolomide in the US. The primary endpoints proposed were PFS-6 and volumetric measurement of residual MRI contrast enhancement. This trial was proposed through the RTOG and the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) but there were major concerns with surgical trial bias and the use of PFS-6 instead of OS as a primary endpoint. The completion of any randomized, phase III study requires absolute blinding of investigators and patients to each arm of the study to be able to assess the primary outcome (e.g., PFS and/or OS) without bias. How could this be possible with a 5-ALA FGS study? With the flick of a switch on the fluorescence-equipped microscope, a surgeon could determine immediately whether the patient received 5-ALA or not by the presence or absence of tumor fluorescence. This could influence the surgeon's decision to properly resect the tumor in an unbiased manner. A surgeon might not perform a maximal tumor resection with conventional white light since they would know that the use of blue light and visualization of fluorescent tumor tissue would provide additional information for further surgical resection.
EOR and OS
Almost two decades of volumetric studies have shown that maximal resection of HGG tumors is associated with a survival advantage in patients [30] [31] [32] [33] . One small, randomized study has shown that surgical resection leads to greater OS of HGG patients when compared to stereotactic biopsy [34] . Greater EOR of HGG tumors is also associated with better efficacy of adjuvant therapies [35] . Most recently, the largest systematic review and quantitative meta-analysis of 41,117 patient examined EOR and OS in newly diagnosed GBM patients and found that complete resection of the contrast enhancing portion of HGGs, or a gross total resection (GTR), was associated with a significant increase in OS and PFS in comparison to subtotal resection [36] . Over 50% of HGG patients, however, do not undergo a GTR of their tumor after conventional surgery based on multiple studies [37, 38] . If 5-ALA can permit more complete resections of HGG tumors, based on randomized, phase III data, then the natural assumption should be a survival benefit for those patients that undergo 5-ALA FGS. Does this constitute patient benefit? 
Initiation of first 5-ALA (Gliolan®) IND in the US

5-ALA as a therapeutic or intraoperative imaging agent: a new standard?
Much of the delay in the US FDA approval of 5-ALA stemmed from its conceptualization as a therapeutic and not as an intraoperative imaging tool. Oncologic therapies are held to a different standard with the FDA approval process that require OS as a primary endpoint and randomized, placebo, controlled studies showing safety and a significant increase in OS with the therapeutic being studied. While safety was established in the phase III study [19] and with 5-ALA administration to thousands of HGG patients globally, the data to confirm a significant OS increase with use of 5-ALA FGS was lacking.
A new standard for FDA approval was needed for 5-ALA as an intraoperative optical imaging agent that provides real-time feedback to the operating surgeon. There was a lack of precedence for FDA approval of an intraoperative optical imaging agent, which was considered a diagnostic/therapeutic crossover, governed by two regulatory paradigms. Cancer drug approval mandates showing clinical patient benefit while imaging drug approval focuses on structural identification. Structural identification relies on how sensitive and specific the agent is at detecting and not detecting cancer and how beneficial this detection is for the patient. 5-ALA, which is selectively taken up by glioma cells in tumors and metabolized to its fluorescent form, protoporphyrin IX, was shown to have unprecedented intraoperative diagnostic accuracy [43] . Multiple biopsy-driven studies confirmed what surgeons around the world knew, that 5-ALA was highly sensitive at detecting malignant tumor tissue [3, [44] [45] [46] [47] [48] [49] . Furthermore, the probability that fluorescent tissue represented malignant tissue, or the positive-predictive value (PPV) of 5-ALA, was close to 100% in almost all studies published [19, 45, 46, 48, 50, 51] .
The specificity and negative-predictive value (NPV), however, were not found to be as high in most biopsydriven studies [45] [46] [47] [51] [52] [53] . Due to the infiltrative biology of HGGs, tumor cells are known to infiltrate centimeters (cm) away from the tumor bulk, which represents the contrast-enhancing portion of tumor [54] . Walter Dandy showed us in 1928 that even after a hemispherectomy in patients with a HGG, tumors can still recur [55] . When biopsies are obtained in HGGs at their infiltrative margin, fluorescence detection is much lower due to the reduced presence of tumor cells with normal cells in the brain [50] .
FDA orphan drug approval and new drug application (NDA)
A successful FDA orphan drug application was submitted for 5-ALA (Gliolan ® ) in 2012 that resulted in orphan designation by the FDA in 2013. The orphan designation of 5-ALA was for the visualization of malignant tissue during surgery for malignant gliomas (WHO grades III and IV). This designation brought new life into the movement for 5-ALA FDA approval in the US based on its strengths as an intraoperative imaging agent.
In 2014, a group of neurosurgeons (Drs. Constantinos Hadjipanayis, Georg Widhalm, and Walter Stummer) and industry experts NXDC and photonamic GmbH and Co. approached the FDA (Medical Imaging Division) to discuss how to move forward with a NDA and FDA approval based on 5-ALA use as an intraoperative diagnostic imaging agent. A pre-investigational NDA (PIND) for 5-ALA was provided to the FDA for the meeting. The intraoperative diagnostic accuracy and safety data of 5-ALA were presented to the Medical Imaging Group at the FDA. No pursuit of claims related to the adequacy of surgical resection or survival with 5-ALA FGS was made during this crucial meeting. A NDA submission was proposed based on 5-ALA as a real-time imaging agent based upon strong PPV data and overwhelming safety in pre-marketing and 26,000 patient post marketing exposure.
After the PIND meeting and extensive communications with the FDA, a NDA would be submitted in December 2016 that consisted of the phase III study results (greater tumor resection and PFS-6 with 5-ALA FGS) and biopsy-driven diagnostic studies (Studies 3, 28, 30) completed (high PPV) ( Table 1) to support 5-ALA use as an intraoperative imaging agent [19, 48, 50] (Fig. 2) . PFS as a surrogate for OS in GBM patients had been shown recently in a meta-analysis from 91 trials [56] . Industry and FDA support for the NDA included painstaking review of all the biopsy-driven data from studies with a focus on the PPV, NPV, sensitivity, specificity, and safety of 5-ALA. The NDA submission and ultimate FDA approval could not have been possible without the support of NXDC and photonamic GmbH and Co. A new standard for regulatory approval of optical imaging agents and devices
5-ALA Medical Advisory Committee Meeting
The 5-ALA regulatory path to approval created a new understanding of the importance of intraoperative detection and delineation of tumor tissue for real-time decisionmaking for surgeons. The appropriate clinical trial endpoints that meet FDA requirements are still ill defined for optical imaging technologies. A 1-day workshop on 4 May 2016, which included representatives from the NCI, the FDA, members of the American Society of Image Guided Surgery, and members of the World Molecular Imaging Society was held to discuss how to better define optical imaging drug/device approval [57] . The workshop provided clarity to the research community on data collection and trial design for approval of novel optical drugs and devices.
Conclusions and moving forward
5-ALA is a reliable diagnostic intraoperative imaging agent that provides real-time guidance to the neurosurgeon that can permit more complete resection of HGGs [43] . The road to 5-ALA (Gleolan ® ) approval in the US uncovered the difficulties associated with regulatory requirements for an intraoperative imaging agent. We believe the 5-ALA regulatory path to approval may permit other intraoperative optical imaging agents to move forward in the future.
